{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:51:32Z","timestamp":1780066292663,"version":"3.54.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["K08EB026503"],"award-info":[{"award-number":["K08EB026503"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["NIHUL1TR000100"],"award-info":[{"award-number":["NIHUL1TR000100"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DOD\/CDMRPPC220278"],"award-info":[{"award-number":["DOD\/CDMRPPC220278"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:35Z","timestamp":1749770135000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Anna M","family":"Dornisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4089-7399","authenticated-orcid":false,"given":"Tyler M","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2025.04.005_bib0001","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0002","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk Prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-019-0163-0","article-title":"The use of 68Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy","volume":"22","author":"Raveenthiran","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0004","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.euo.2020.01.002","article-title":"Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy","volume":"4","author":"Jansen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer","author":"Zumsteg","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0006","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ijrobp.2023.02.039","article-title":"Patterns of failure in men with radiorecurrent prostate cancer: a post hoc analysis of 3 prospective gallium 68 prostate-specific membrane antigen positron emission tomography\/computed tomography imaging trials","volume":"116","author":"Smith","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage","volume":"169","author":"Maitre","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0011","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2002.01.086","article-title":"Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases","volume":"20","author":"Coen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2019.10.008","article-title":"Local failure and survival after definitive radiotherapy for aggressive prostate cancer: an individual patient-level meta-analysis of six randomized trials","volume":"77","author":"Kishan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0013","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 gy of radiotherapy with 78 gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0017","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0018","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0020","doi-asserted-by":"crossref","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient\u2013data network meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0023","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0026","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol,"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0029","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0030","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose\u2013effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0032","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-023-02375-5","article-title":"Use of focal radiotherapy boost for prostate cancer: radiation oncologists\u2019 perspectives and perceived barriers to implementation","volume":"18","author":"Zhong","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0033","doi-asserted-by":"crossref","unstructured":"Dornisch, A, Zhong, A, Poon, D, et al. Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review. World J Urol doi:10.1007\/s00345-023-04745-w.","DOI":"10.1007\/s00345-023-04745-w"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0034","doi-asserted-by":"crossref","unstructured":"C.C. Conlin, C.H. Feng, A.E. Rodriguez-Soto, et al., Improved characterization of diffusion in normal and cancerous prostate tissue through optimization of multicompartmental signal models, J Magn Reson Imaging, 53, 2021, 628\u2013639.","DOI":"10.1002\/jmri.27393"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13014-020-01689-y","article-title":"Automated contouring and planning pipeline for hippocampal-avoidant whole-brain radiotherapy","volume":"15","author":"Feng","year":"2020","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0036","author":"Domingo"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0037","author":"Do"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0038","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","volume":"117","author":"Lui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0039","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/mp.14584","article-title":"Deformable MR-CBCT prostate registration using biomechanically constrained deep learning networks","volume":"48","author":"Fu","year":"2021","journal-title":"Med Phys"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2019.11.015","article-title":"Framework for evaluation of automated knowledge-based planning systems using multiple publicly available prostate routines","volume":"10","author":"Ray","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.phro.2020.09.009","article-title":"Clinical experience and workflow challenges with magnetic resonance-only radiation therapy simulation and planning for prostate cancer,","volume":"16","author":"Tyagi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0042","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13014-020-01513-7","article-title":"MR-PROTECT: clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria","volume":"15","author":"Persson","year":"2020","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0043","article-title":"Clinical impact of contouring variability for prostate cancer tumor boost","author":"Zhong","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0044","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.brachy.2016.12.015","article-title":"Brachytherapy boost for prostate cancer: trends in care and survival outcomes","volume":"16","author":"Glaser","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2021.07.004","article-title":"PSA: declining utilization of prostate brachytherapy","volume":"21","author":"Andring","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0046","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijrobp.2018.10.023","article-title":"Brachytherapy training survey of radiation oncology residents","volume":"103","author":"Marcrom","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0047","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2020.09.025","article-title":"Challenges influencing the utilization of prostate brachytherapy in the United States","volume":"154","author":"Odei","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0048","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.brachy.2020.07.003","article-title":"#ThisIsBrachytherapy: increasing awareness of brachytherapy","volume":"20","author":"Kahn","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0049","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.brachy.2022.04.006","article-title":"Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost","volume":"21","author":"Kollmeier","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2020.05.029","article-title":"Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: dosimetry, toxicity and health related quality of life","volume":"149","author":"Sanmamed","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0051","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0052","doi-asserted-by":"crossref","first-page":"110535","DOI":"10.1016\/j.radonc.2024.110535","article-title":"Intra-prostatic recurrences after radiotherapy with focal boost: location and dose mapping in the FLAME trial","volume":"201","author":"Menne Guricov\u00e1","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0053","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial","volume":"86","author":"van As","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0054","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0055","doi-asserted-by":"crossref","first-page":"110568","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0056","first-page":"22","article-title":"PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0057","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00259-020-05059-4","article-title":"Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer","volume":"48","author":"Draulans","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0058","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","article-title":"Intraindividual comparison between 68Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients","volume":"47","author":"Spohn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0059","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard \u2013 Implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0061","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.ijrobp.2023.06.427","article-title":"Toxicity and patient reported quality of life after PSMA-PET and mpMRT-based focal dose escalated definitive radiotherapy in prostate cancer patients: 2-year follow-up of the HypoFocal Phase II trial","volume":"117","author":"Spohn","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0062","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric Phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0063","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.005_bib0064","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11985","article-title":"Evaluation of the use of cancer registry data for comparative effectiveness research","volume":"3","author":"Kumar","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:05:51Z","timestamp":1750791951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000347"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.005","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}